NCCN Guidelines® Insights - Prostate Cancer, Version 1.2021
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. This article summarizes the panel’s discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
Category
  • Prostate Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Clinical Scenario #4: Evolving Applications of PARP Inhibitors in Various Cancers
This activity will address the increasing use of PARP inhibitors in the management of patients with solid tumors, the factors affecting the selection of the appropriate tests, challenges of interpreting test results and communicating the results to patients, and new developments in biomarker testing.
Category
  • Breast Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation